Literature DB >> 29180028

Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.

Bikash Sahay1, Natacha Colliou2, Mojgan Zadeh2, Yong Ge2, Minghao Gong2, Jennifer L Owen1, Melissa Valletti1, Christian Jobin2, Mansour Mohamadzadeh3.   

Abstract

Clostridium botulinum readily persists in the soil and secretes life-threatening botulinum neurotoxins (BoNTs) that are categorized into serotypes A to H, of which, serotype A (BoNT/A) is the most commonly occurring in nature. An efficacious vaccine with high longevity against BoNT intoxication is urgent. Herein, we developed a dual-route vaccine administered over four consecutive weeks by mucosal and parenteral routes, consisting of the heavy chain (Hc) of BoNT/A targeting dendritic cell peptide (DCpep) expressed by Lactobacillus acidophilus as a secretory immunogenic protein. The administered dual-route vaccine elicited robust and long-lasting memory B cell responses comprising germinal center (GC) B cells and follicular T cells (Tfh) that fully protected mice from lethal oral BoNT/A fatal intoxication. Additionally, passively transferring neutralizing antibodies against BoNT/A into naïve mice induced robust protection against BoNT/A lethal intoxication. Together, a targeted vaccine employing local and systemic administrative routes may represent a novel formulation eliciting protective B cell responses with remarkable longevity against threatening biologic agents such as BoNTs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B cells; Botulinum neurotoxins; Dendritic cells; Dual-route vaccine; Target vaccine

Mesh:

Substances:

Year:  2017        PMID: 29180028      PMCID: PMC6180320          DOI: 10.1016/j.vaccine.2017.11.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

Review 1.  New insights into the enigma of immunoglobulin D.

Authors:  Kang Chen; Andrea Cerutti
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 3.  Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Trends Mol Med       Date:  2009-05-30       Impact factor: 11.951

Review 4.  Immunological mechanisms of vaccination.

Authors:  Bali Pulendran; Rafi Ahmed
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

5.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

6.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

7.  Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge.

Authors:  M Mohamadzadeh; T Duong; S J Sandwick; T Hoover; T R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-25       Impact factor: 11.205

Review 8.  Management of botulism.

Authors:  Renee F Robinson; Milap C Nahata
Journal:  Ann Pharmacother       Date:  2003-01       Impact factor: 3.154

9.  Learning vaccinology from viral infections.

Authors:  Rafi Ahmed; Bali Pulendran
Journal:  J Exp Med       Date:  2011-11-21       Impact factor: 14.307

Review 10.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

View more
  4 in total

1.  Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E.

Authors:  Zhen Li; Jiansheng Lu; Xiao Tan; Rong Wang; Qing Xu; Yunzhou Yu; Zhixin Yang
Journal:  Toxins (Basel)       Date:  2022-02-11       Impact factor: 4.546

2.  Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin.

Authors:  Zhen Li; Jian-Sheng Lu; Shan Liu; Rong Wang; Qing Xu; Yun-Zhou Yu; Zhi-Xin Yang
Journal:  Neurotox Res       Date:  2021-02-22       Impact factor: 3.911

Review 3.  Engineering Components of the Lactobacillus S-Layer for Biotherapeutic Applications.

Authors:  Courtney Klotz; Rodolphe Barrangou
Journal:  Front Microbiol       Date:  2018-10-02       Impact factor: 5.640

Review 4.  Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines.

Authors:  Allison C Vilander; Gregg A Dean
Journal:  Vaccines (Basel)       Date:  2019-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.